Humacyte FY2024 EPS Forecast Raised by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of Humacyte in a report issued on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.40) for the year, up from their prior forecast of ($1.41). Cantor Fitzgerald has a "Overweight" rating and a $13.00 price target on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share.

HUMA has been the subject of a number of other reports. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. HC Wainwright restated a "buy" rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. BTIG Research reiterated a "buy" rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Monday, January 13th. Finally, TD Cowen reiterated a "buy" rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Humacyte presently has a consensus rating of "Buy" and an average target price of $13.71.

Humacyte Stock Performance

Shares of HUMA traded down $0.07 during trading hours on Friday, hitting $4.41. The company had a trading volume of 2,264,931 shares, compared to its average volume of 7,907,899. The stock has a market capitalization of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32. The firm has a fifty day moving average price of $4.58 and a 200-day moving average price of $5.66. Humacyte has a 52-week low of $2.53 and a 52-week high of $9.97.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in shares of Humacyte by 62.7% in the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company's stock worth $1,219,000 after buying an additional 97,931 shares in the last quarter. Rhumbline Advisers lifted its stake in Humacyte by 87.8% in the 2nd quarter. Rhumbline Advisers now owns 110,919 shares of the company's stock worth $532,000 after purchasing an additional 51,858 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock valued at $2,881,000 after purchasing an additional 524,600 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Humacyte during the second quarter valued at about $110,000. Finally, Profund Advisors LLC bought a new stake in shares of Humacyte in the second quarter worth about $97,000. 44.71% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Laura E. Niklason sold 811,172 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares in the company, valued at $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares of the company's stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last ninety days. Corporate insiders own 11.20% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.